Welcome back to your monthly news roundup, where we take a look back at the top moments to hit the pharma headlines. It’s time to reflect on April 2026
A dog-eat-dog weight loss world
April saw a flurry of activity across the obesity market, with Eli Lilly and Company and Novo Nordisk locking horns on multiple fronts.
On 1 April, Lilly’s orforglipron became the second oral GLP-1 approved by the FDA for weight management, entering a market Novo had opened just months earlier with oral semaglutide. Although both target the GLP-1 receptor, the two pills are formulated differently: orforglipron is a small-molecule drug, meaning – unlike peptide-based oral semaglutide – it can be taken without food or timing restrictions. In separate phase 3 trials, orforglipron delivered average weight loss of 12.4%, compared with 16.6% reported for oral semaglutide. But with fewer than one in ten eligible patients currently using GLP-1s, there is room for both.
Beyond the oral race, April also brought injectable data that may strengthen Novo’s position. A real-world analysis of roughly 8,000 patients found tirzepatide users lost 2% more lean body mass than semaglutide users at 12 months. Among those losing more than 20% of body weight, around 10% of tirzepatide users lost more than 5% lean mass, compared with fewer than 7% of semaglutide users. For Lilly, which has led on headline weight loss numbers, this potentially complicates its narrative. It’s worth noting that the data is pre-peer-review, but in a market this competitive, any perceived advantage matters.
Shock to the system
When the US-Israeli-Iran conflict began in February, the pharmaceutical industry was tested in ways it was not prepared for. By April, the impact of that unpreparedness was clear, with data science firm Phesi finding 6.7% of global clinical trials had been disrupted.
The heaviest fallout hit lung cancer, breast cancer, multiple myeloma and heart failure studies – disease areas with large patient populations and major unmet need. Generic manufacturers faced a parallel crisis: freight rates spiked 55-70% in early March, and with 10-20% of global pharmaceutical commerce routed through the Middle East, thin-margin API producers had little buffer.
On top of this, only 22% of pharma firms were actively running geopolitical risk assessments at the end of 2025, according to Argon & Co – despite COVID-19, the 2021 Suez Canal blockage and the 2024 Red Sea disruptions offering near-identical warnings. The lesson, apparently, is one that has not yet been learned.
Silicon Valley scrubs in
If the supply chain crisis exposed the pharmaceutical industry’s fragilities, April’s artificial intelligence developments showed an sector attempting to future-proof itself.
The month’s three major AI moves shared a common thread: big tech embedding itself deeper into the drug development world, from molecule discovery to solving complex business needs. Amazon Web Services launched Amazon Bio Discovery, OpenAI unveiled GPT-Rosalind – named after Rosalind Franklin – and Novo Nordisk announced a strategic partnership with OpenAI spanning its R&D, manufacturing and commercial functions. Together, they highlight how a new way of working is being built, and who is leading it.
Already, the results look promising. Memorial Sloan Kettering Cancer Center used Amazon Bio Discovery to generate 300,000 antibody candidates, narrowing them down to 100,000 for testing in weeks rather than years. Meanwhile, GPT-Rosalind, covering genomics, protein engineering and biochemistry, exceeded the 95th percentile of human experts on RNA prediction tasks in early testing, showing its potential in the field.
Honourable mention of the month
In late April, Moderna dosed the first participants in a phase 3 trial of its bird flu vaccine, making it the first mRNA candidate to reach late-stage human testing. This came despite Robert F. Kennedy Jr.‘s Department of Health and Human Services cutting the trial’s funding last year, leading the company to secure $54.3m from the Coalition for Epidemic Preparedness Innovations instead. With 71 human bird flu cases recorded in the US since 2024 and no confirmed human-to-human transmission, the threat remains latent – but, as COVID-19 demonstrated, that can change in the blink of an eye.
